Home > News > Nanogen Announces Patent for Fluorescent Detection of Nucleic Acid Targets
October 11th, 2005
Nanogen Announces Patent for Fluorescent Detection of Nucleic Acid Targets
Abstract:
Nanogen, Inc., developer of advanced diagnostic products, announced today its subsidiary, Epoch Biosciences, was issued Patent No. 6,951,930, "Hybridization-Triggered Fluorescent Detection of Nucleic Acids" by the U.S. Patent and Trademark Office. The '930 patent relates to latent fluorophore-minor groove binder oligonucleotide conjugates which fluoresce upon hybridization to a target. The conjugates may be used to detect nucleic acid targets.
Source:
Nanogen
Related News Press |
Nanomedicine
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Announcements
Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024
Finding quantum order in chaos May 17th, 2024
Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||